Oxford Endovascular, a spin-out from Oxford University, has used 'origami engineering for the brain' to develop a unique, patented, next-generation flow-diverter (OxiFlow) for the minimally invasive treatment of intracranial aneurysms - a market around $1 Billion, 8% CAGR. The device has been designed by world leading Professors of Medicine & Engineering.

OxiFlow, is inserted via keyhole surgery, curing weaknesses in brain blood vessels at risk of bursting which would cause death / disability.  Current flow diverters are costly and often require multiple placements due to design limitations. OxiFlow, is designed to expand usage needing only one insertion saving time and cost.

OxiFlow has a unique patented design based on physician feedback enabling it to become the market leading device. It is laser cut from nitinol and overcomes the design challenges of existing technologies that are braided metal stents with poor radial force.

OxiFlow places more accurately offering a wider range of patients, safer, more effective and less costly treatment. It also gives the physician total control over the deployment of the device and advancement of its bespoke delivery system.

The unique technology is in its final stages of animal studies and planning to enter a CE mark study in 2020 allowing commercialization in 2023.

Oxford Endovascular will be presenting its 2019 investment opportunity at the Biotech Showcase:

 

Date: Wednesday, January 9, 2019

Time: 10:30 AM

Location: Parc 55 (a Hilton Hotel), 55 Cyril Magnin Street, San Francisco, CA 94102

Track: Powell - II (Level 3)